 |
Raptor Pharmaceutical Added to NASDAQ Biotechnology Index
May 14, 2012
|
20.1 KB |
|
| |
NOVATO, Calif., May 14, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that NASDAQ is adding Raptor to the NASDAQ Biotechnology Index (NASDAQ: NBI and XNBI). The NBI includes seasoned NASDAQ Global Market and Global Select issuers classified as biotech or pharmaceutical companies with a min...
|
|
Raptor Pharmaceutical Announces Publication of Phase 3 Results in the Clinical Journal of the American Society of Nephrology
May 3, 2012
|
26.8 KB |
|
| |
NOVATO, Calif., May 3, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced the online publication of an article titled, "A Randomized Controlled Crossover Trial with a Delayed Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on WBC Cystine Levels and Comparison of Safety" ...
|
|
Raptor Pharmaceutical Corp. to Present at Two Upcoming Investor Conferences
May 3, 2012
|
20.1 KB |
|
| |
NOVATO, Calif., May 3, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will present an overview of the Company at two investor conferences in May.
The conference presentation schedule is as follows:
...
|
|
Raptor Pharmaceutical Announces At-the-Market Common Stock Sales Program
May 1, 2012
|
27.4 KB |
|
| |
NOVATO, Calif., May 1, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that it has entered into an "At-the-Market" ("ATM") Sales Agreement, dated April 30, 2012, with Cowen and Company, LLC ("Cowen"), under which Raptor may, at its discretion, sell its common stock with a sales value o...
|
|
Raptor Pharmaceutical Receives Notices of Allowance for Key European Patent Applications Protecting Its Cysteamine Portfolio
Apr 12, 2012
|
28.6 KB |
|
| |
NOVATO, Calif., April 12, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the European Patent Office has issued a Notice of Allowance for a key patent covering the use of enteric-coated, delayed-release ("DR") oral formulations of cysteamine bitartrate, including Raptor's propriet...
|
|
Raptor Pharmaceutical Corp. to Present at Cystinosis Research Foundation Day of Hope Family Conference
Apr 12, 2012
|
27.6 KB |
|
| |
NOVATO, Calif., April 12, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that Ted Daley, President, will present an update on its investigational drug candidate, Cysteamine Bitartrate Delayed-Release Capsules (RP103), for the potential treatment of nephropathic cystinosis at the Cystin...
|
|
Raptor Pharmaceutical Corp. Submits New Drug Application for RP103 for the Potential Treatment of Nephropathic Cystinosis
Mar 30, 2012
|
24.1 KB |
|
| |
NOVATO, Calif., March 30, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) announced that it submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") seeking approval to market its investigational drug candidate, Cysteamine Bitartrate Delayed-release Capsules (RP103), fo...
|
|
Raptor Pharmaceutical Corp. Announces the Appointment of Henk Doude van Troostwijk as General Manager of European Commercial Operations
Mar 28, 2012
|
24.0 KB |
|
| |
NOVATO, Calif., March 28, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced the appointment of Henk Doude van Troostwijk as its General Manager of European Commercial Operations, effective April 15, 2012. Mr. Doude van Troostwijk will be responsible for building and managing Raptor's commercia...
|
|
Raptor Pharmaceutical Corp. Announces EMA Validation of Marketing Authorization Application for RP103 for the Treatment of Nephropathic Cystinosis
Mar 26, 2012
|
23.9 KB |
|
| |
NOVATO, Calif., March 26, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that the European Medicines Agency ("EMA") has determined that Raptor's Marketing Authorization Application ("MAA") for its investigational drug candidate, RP103 for the potential treatment of nephropathic cystinosis, ...
|
|
Raptor Pharmaceutical Corp. Upgraded to Trade on the NASDAQ Global Market
Mar 2, 2012
|
20.0 KB |
|
| |
NOVATO, Calif., March 2, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that the Company has been upgraded to trade on the NASDAQ Global Market. Shares of Raptor's common stock began trading on the NASDAQ Global Market on February 29, 2012 and will continue to be traded under the ticke...
|
|
Raptor Pharmaceutical Corp. to Present at Three Upcoming Investor Conferences
Feb 10, 2012
|
20.2 KB |
|
| |
NOVATO, Calif., Feb. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that its Chief Executive Officer, Christopher M. Starr, Ph.D., will present an overview of the Company at three investor conferences in February.
The conference presentation schedule is as follows:
...
|
|
Raptor Pharmaceutical Corp. to Present at the 30th Annual JP Morgan Healthcare Conference
Jan 4, 2012
|
12.3 KB |
|
| |
NOVATO, Calif., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's Chief Executive O...
|
|
Raptor Pharmaceutical Corp. Provides Program Update on RP103 (DR Cysteamine) for Nephropathic Cystinosis
Dec 21, 2011
|
17.0 KB |
|
| |
NOVATO, Calif., Dec. 21, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) announced today a program update for its lead investigational compound, RP103...
|
|
Raptor Pharmaceutical Corp. Signs Collaborative Research and Development Agreement With NIDDK on Phase 2b Clinical Trial of RP104 (DR Cysteamine Tablets) in Non-Alcoholic Steatohepatitis ("NASH")
Dec 19, 2011
|
19.4 KB |
|
| |
NOVATO, Calif., Dec. 19, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the signing of a cooperative research and development agreement ("CRADA") w...
|
|
Raptor Pharmaceutical Corp. to Present at the Oppenheimer 22nd Annual Healthcare Conference
Dec 13, 2011
|
11.3 KB |
|
| |
NOVATO, Calif., Dec. 13, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's Chief Executive ...
|
|
Raptor Pharmaceutical Corp. to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Nov 9, 2011
|
9.5 KB |
|
| |
NOVATO, Calif., Nov 9, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Ted Daley, President of Raptor will present an overview of the Company at the Lazard Capital Markets 8th Annual Healthcare Conference. Raptor's presentation will take place at The Pierre Hote...
|
|
Raptor Pharmaceutical Corp. Holds Pre-NDA Meeting With FDA for RP103 for Nephropathic Cystinosis
Oct 25, 2011
|
14.0 KB |
|
| |
NOVATO, Calif., Oct 25, 2011 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced today that the Company concluded a pre-New Drug Application ("NDA") meeting with the U.S. Food and Drug Administration ("FDA") related to its investigational drug candidate, RP103 (delayed-release formulatio...
|
|
Raptor Pharmaceutical Corp. to Present at the BioCentury NewsMakers Conference
Oct 13, 2011
|
9.5 KB |
|
| |
NOVATO, Calif., Oct 13, 2011 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Patrick Reichenberger, VP, Commercial Operations of Raptor will present an overview of the Company at the 2011 BioCentury NewsMakers in the Biotech Industry Conference. Raptor's presentation will ...
|
|
Raptor Pharmaceutical Corp. to Present at JMP Securities Healthcare Conference
Sep 22, 2011
|
9.6 KB |
|
| |
NOVATO, Calif., Sep 22, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Christopher M. Starr, Ph.D., co-founder and Chief Executive Officer of Raptor will present an overview of the Company at the JMP Securities Healthcare Conference. Raptor's presentation will ...
|
|
Raptor Pharmaceutical Corp. Announces Closing of Public Offering of Common Stock
Sep 13, 2011
|
12.1 KB |
|
| |
NOVATO, Calif., Sep 13, 2011 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the closing of its previously announced underwritten public offering of shares of its common stock at a price to the public of $4.00 per share. The shares sold in the offering included 10,000,000...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz